10-Q: Stereotaxis Q2 2026: Revenue Dips Amidst Acquisition Integration

Stereotaxis reported a decrease in Q2 2026 revenue to $7.7 million, primarily driven by lower system sales, while net loss widened, despite progress in product development and the recent acquisition of Robocath.

Summary

• Stereotaxis reported a 13% decrease in revenue for the three months ended June 30, 2026, to $7.7 million, compared to $8.8 million in the prior year period.
• System revenue declined by 51% to $1.5 million, while revenue from disposables, service, and accessories increased by 7% to $6.2 million.
• The company incurred a net loss of $4.5 million for the quarter, an increase from $3.8 million in the same period last year.
• For the six months ended June 30, 2026, revenue decreased by 14% to $14.0 million, with a net loss of $10.3 million.
• The acquisition of Robocath was completed on July 7, 2026, for approximately $20.0 million in cash and stock, with potential for up to $25.0 million in additional earnout consideration.
• The company ended the quarter with $10.5 million in cash and cash equivalents.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as slightly negative due to declining revenues and continued net losses, despite strategic acquisitions and product development progress.

Positives

• Revenue from disposables, service, and accessories increased by approximately 7% to $6.2 million for the three months ended June 30, 2026.
• Gross margin improved to 58% for the three months ended June 30, 2026, from 52% in the prior year period, due to a favorable product mix.
• The company received FDA 510(k) clearance for the GenesisX RMN System in Q4 2025 and for the Synchrony Solution in April 2026.
• The Stereotaxis MAGiC catheter received FDA 510(k) clearance in January 2026, and MAGiC Sweep received clearance in July 2025.
• The acquisition of Robocath was completed, expanding the company's robotic technology portfolio in interventional cardiology and neurointerventions.

Negatives

• Total revenue decreased by 13% to $7.7 million for the three months ended June 30, 2026.
• Revenue from systems sales decreased significantly by 51% to $1.5 million for the three months ended June 30, 2026.
• Net loss for the quarter increased to $4.5 million from $3.8 million in the prior year period.
• For the six months ended June 30, 2026, revenue decreased by 14% to $14.0 million, and net loss widened to $10.3 million.
• The company continues to incur significant cumulative net losses, totaling approximately $593.7 million as of June 30, 2026.
• The transition from Johnson & Johnson supplied catheters to Stereotaxis-supplied MAGiC catheters is impacting disposable revenue.

Risks

• Macroeconomic and geopolitical factors, including tariffs, supply chain challenges, inflation, and interest rates, could adversely impact future results.
• The integration of Robocath presents risks, including the ability to retain key personnel, manufacture and commercialize products, and manage international operations.
• The company faces uncertainty regarding the continued supply of J&J catheters and the transition to its own MAGiC catheter.
• Tariff changes and trade regulations could increase costs and negatively impact sales in certain markets, particularly China.
• Disruptions to capital markets could affect the company's ability to raise additional funding.
• The company's hospital customers face their own financial and operational pressures, which could lead to delays or cancellations of orders.

Future Outlook

The company expects to incur additional losses in 2026 due to continued product development, commercialization efforts, R&D activities, sales and marketing initiatives, and funding Robocath's operations. Management believes current cash and cash equivalents are sufficient to fund operations and capital requirements, but acknowledges the possibility of needing additional funding due to macroeconomic uncertainties and integration of Robocath.

Management Comments

• StockSavvy.ai notes that management believes its existing cash and cash equivalents will be sufficient to fund operating expenses and capital equipment requirements, including anticipated funding for Robocath's operations and development activities.
• Management acknowledges the uncertainties associated with integrating and funding Robocath and the macroeconomic environment, stating they cannot guarantee additional funding will not be needed.
• Management is continuing to monitor the impact of the macroeconomic environment on project timing, regulatory approvals, customer and supplier operations, and operating results.

Industry Context

StockSavvy.ai observes that Stereotaxis operates in the highly competitive and rapidly evolving medical device market, specifically focusing on robotic navigation for endovascular interventions. The company's strategy to expand beyond electrophysiology into coronary, neuro, and peripheral interventions aligns with broader industry trends towards minimally invasive procedures and advanced robotic assistance. The recent acquisition of Robocath further strengthens its position in mechanical robotic technology.

Comparison to Industry Standards

• The company's gross margin of 58% for Q2 2026 is a key metric. While improving from 52% in the prior year, it needs to be compared against industry benchmarks for medical device manufacturers, which can vary significantly by sub-sector. For instance, companies focused purely on disposables might have higher gross margins than those with significant capital equipment sales.
• The reported net loss of $4.5 million for Q2 2026 and cumulative losses of $593.7 million highlight a common challenge for innovative medical technology companies investing heavily in R&D and market penetration. Many companies in this space, such as Intuitive Surgical (ISRG) in its early years, also experienced periods of net losses before achieving profitability.
• The company's revenue decline in systems sales is a concern. Competitors like Medtronic (MDT) and Johnson & Johnson (JNJ) in their respective surgical robotics divisions often report growth in capital equipment sales, though this can be cyclical. Stereotaxis's reliance on recurring revenue from disposables is a positive sign, as this is a common and often more stable revenue stream in the medical device industry.

Legal Proceedings

• Stereotaxis had $6.3 million of insurance receivables and $6.3 million of legal contingencies recorded as accrued legal liabilities related to ongoing litigation as of June 30, 2026.
• A vendor filed UCC financing statements on underlying inventory for approximately $0.6 million, which the company is contesting.

Stakeholder Impact

• Shareholders may experience dilution if the company utilizes its at-the-market offering program or future equity financings.
• Employees' stock-based compensation is subject to performance milestones and vesting periods.
• Customers (hospitals) may face challenges in funding capital purchases due to macroeconomic pressures, potentially impacting sales cycles and demand for systems and disposables.
• Suppliers may be affected by increased costs due to tariffs and supply chain disruptions, which could be passed on to Stereotaxis.

Next Steps

• Continue to advance adoption of robotic magnetic navigation systems and proprietary devices in markets with regulatory clearance.
• Work with regulatory authorities in geographies where approval is pending.
• Fund Robocath's ongoing operations and development of its next-generation R-Two products.
• Monitor the impact of the macroeconomic environment on project timing, regulatory approvals, and customer/supplier operations.
• Continue to explore financing alternatives.

Key Dates

Recommendation

The company shows progress in product development and strategic acquisitions, but the declining revenue, increasing net loss, and ongoing cumulative losses present significant headwinds. The successful integration of Robocath and future market adoption of new products are key to a turnaround. Given the current financial performance and market uncertainties, a 'hold' recommendation is prudent, awaiting clearer signs of revenue stabilization and profitability.

Keywords

Robotic Magnetic Navigation, Interventional Cardiology, Electrophysiology, Cardiac Ablation, Medical Devices, Robocath Acquisition, Catheter Technology, Revenue Decline